Literature DB >> 21808989

Utilization of health care databases for pharmacoepidemiology.

Yasuo Takahashi1, Yayoi Nishida, Satoshi Asai.   

Abstract

Pharmacoepidemiology is the study of the utilization and effects of drugs in clinical and population settings, and the outcomes of drug therapy. The growing trend of recording computerized data that will increasingly be automated into health care delivery is making the use of large datasets more and more common in pharmacoepidemiologic research. Most retrospective databases offer large populations and longer observation periods with real-world practice and can answer a variety of research questions quickly and cost-effectively. Observational studies, specifically using large databases, can complement findings from randomized clinical trials (RCTs) by assessing treatment effectiveness in patients encountered in daily clinical practice, although they are more exposed to bias and certainly are lower on the hierarchy of evidence than RCTs. Furthermore, careful defining of the research question with appropriate design and application of advanced statistical techniques, e.g., propensity-score analysis or marginal structural models, can yield findings with validity and improve causal inference of treatment effects. Some existing guidelines for comparative effectiveness help decision makers to evaluate the quality of observational studies comparing the effectiveness of various medical products and services. Thus, the trend for utilization of databases for pharmacoepidemiology will continue to grow in coming years.

Entities:  

Mesh:

Year:  2011        PMID: 21808989     DOI: 10.1007/s00228-011-1088-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

1.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

Review 2.  Principles for modeling propensity scores in medical research: a systematic literature review.

Authors:  Sherry Weitzen; Kate L Lapane; Alicia Y Toledano; Anne L Hume; Vincent Mor
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-12       Impact factor: 2.890

3.  GRACE principles: recognizing high-quality observational studies of comparative effectiveness.

Authors:  Nancy A Dreyer; Sebastian Schneeweiss; Barbara J McNeil; Marc L Berger; Alec M Walker; Daniel A Ollendorf; Richard E Gliklich
Journal:  Am J Manag Care       Date:  2010-06       Impact factor: 2.229

Review 4.  Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review.

Authors:  Baiju R Shah; Andreas Laupacis; Janet E Hux; Peter C Austin
Journal:  J Clin Epidemiol       Date:  2005-04-19       Impact factor: 6.437

Review 5.  Indications for propensity scores and review of their use in pharmacoepidemiology.

Authors:  Robert J Glynn; Sebastian Schneeweiss; Til Stürmer
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-03       Impact factor: 4.080

6.  Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.

Authors:  Marc L Berger; Muhammad Mamdani; David Atkins; Michael L Johnson
Journal:  Value Health       Date:  2009-09-29       Impact factor: 5.725

7.  observational studies: propensity score analysis of non-randomized data.

Authors:  M Trojano; F Pellegrini; D Paolicelli; A Fuiani; V Di Renzo
Journal:  Int MS J       Date:  2009-09

8.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

Review 9.  From randomized controlled trials to observational studies.

Authors:  Stuart L Silverman
Journal:  Am J Med       Date:  2009-02       Impact factor: 4.965

10.  Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.

Authors:  Andrew N Freedman; Leah B Sansbury; William D Figg; Arnold L Potosky; Sheila R Weiss Smith; Muin J Khoury; Stefanie A Nelson; Richard M Weinshilboum; Mark J Ratain; Howard L McLeod; Robert S Epstein; Geoffrey S Ginsburg; Richard L Schilsky; Geoffrey Liu; David A Flockhart; Cornelia M Ulrich; Robert L Davis; Lawrence J Lesko; Issam Zineh; Gurvaneet Randhawa; Christine B Ambrosone; Mary V Relling; Nat Rothman; Heng Xie; Margaret R Spitz; Rachel Ballard-Barbash; James H Doroshow; Lori M Minasian
Journal:  J Natl Cancer Inst       Date:  2010-10-13       Impact factor: 13.506

View more
  20 in total

1.  The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.

Authors:  Christian G Reich; Patrick B Ryan; Marc A Suchard
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

2.  Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches.

Authors:  Guillermo Prada-Ramallal; Bahi Takkouche; Adolfo Figueiras
Journal:  Drug Saf       Date:  2017-07       Impact factor: 5.606

3.  Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications.

Authors:  Arton Baftiu; Cecilie Johannessen Landmark; Ida Rudberg Rusten; Silje Andrea Feet; Svein I Johannessen; Pål G Larsson
Journal:  Eur J Clin Pharmacol       Date:  2016-07-13       Impact factor: 2.953

4.  Multimorbidity medications and poor asthma prognosis.

Authors:  Sébastien Chanoine; Margaux Sanchez; Isabelle Pin; Sofia Temam; Nicole Le Moual; Agnès Fournier; Christophe Pison; Jean Bousquet; Pierrick Bedouch; Marie-Christine Boutron-Ruault; Raphaëlle Varraso; Valérie Siroux
Journal:  Eur Respir J       Date:  2018-04-12       Impact factor: 16.671

5.  Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study.

Authors:  Jean-Pascal Fournier; Agnès Sommet; Robert Bourrel; Stéphane Oustric; Atul Pathak; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2012-04-15       Impact factor: 2.953

6.  The intriguing future of pharmacoepidemiology.

Authors:  Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

7.  Long-Term Neurodevelopmental Outcomes in Children and Adolescents With Congenital Heart Disease.

Authors:  Jeanette M Jerrell; C Osborne Shuler; Avnish Tripathi; George B Black; Yong-Moon Mark Park
Journal:  Prim Care Companion CNS Disord       Date:  2015-10-22

8.  Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes.

Authors:  Yayoi Nishida; Yasuo Takahashi; Tomohiro Nakayama; Satoshi Asai
Journal:  Cardiovasc Diabetol       Date:  2012-05-17       Impact factor: 9.951

9.  Comparative effect of clopidogrel and aspirin versus aspirin alone on laboratory parameters: a retrospective, observational, cohort study.

Authors:  Yasuo Takahashi; Yayoi Nishida; Tomohiro Nakayama; Satoshi Asai
Journal:  Cardiovasc Diabetol       Date:  2013-06-14       Impact factor: 9.951

10.  Comparative effect of clopidogrel plus aspirin and aspirin monotherapy on hematological parameters using propensity score matching.

Authors:  Masatoshi Hayasaka; Yasuo Takahashi; Yayoi Nishida; Yoshikazu Yoshida; Shinji Hidaka; Satoshi Asai
Journal:  Vasc Health Risk Manag       Date:  2013-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.